NEW YORK, Jan. 26 (GenomeWeb News) - Genaissance Pharmaceuticals has exclusively licensed commercial rights to a patent held by Vanderbilt University that it said would expand its ability to provide genetic tests for variants of cardiac ion-channel proteins involved in drug-induced cardiac arrhythmias.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.